EphA2 T-cell epitope agonists and uses therefore
EphA2 T-cell epitope are provided herein. The epitopes include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitopes are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The epitopes also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 epitopes also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.
1. An isolated peptide that consists of 9-35 amino acid residues, wherein said isolated peptide comprises the peptide of SLLGLKDQV (SEQ ID NO: 2, residues 961-969), GLTRTSVTV (SEQ ID NO: 2, residues 391-399), KLNVEERSV (SEQ ID NO: 2, residues 162-170) or MQNVIMNDMP (SEQ ID NO: 2, residues 55-63),
where said peptide of SLLGLKDQV (SEQ ID NO: 2, residues 961-969), GLTRTSVTV (SEQ ID NO: 2, residues 391-399), KLNVEERSV (SEQ ID NO: 2, residues 162-170) or MQNIMNDMP (SEQ ID NO: 2, residues 55-63):
(i) has up to one conservative amino acid substitution within the conservative substitution groups (a) S and T, (b) L, I and V, and (c) E and D; and
(ii) retains the ability to stimulate a T-cell immune response to EphA2 as determined by ELISPOT assay.
2. The isolated peptide of claim 1 , comprising the peptide SLLGLKDQV (SEQ ID NO: 2, residues 961-969).
3. The isolated peptide of claim 1 , comprising the peptide GLTRTSVTV (SEQ ID NO: 2, residues 391-399).
4. The isolated peptide of claim 1 , comprising the peptide KLNVEERSV (SEQ ID NO: 2, residues 162-170).
5. The isolated peptide of claim 1 , comprising the peptide MQNIMNDMP (SEQ ID NO: 2, residues 55-63).
6. A vaccine formulation comprising an isolated peptide that consists of 9-35 amino acid residues, wherein said isolated peptide comprises the peptide of SLLGLKDQV (SEQ ID NO: 2, residues 961-969), GLTRTSVTV (SEQ ID NO: 2, residues 391-399), KLNVEERSV (SEQ ID NO: 2, residues 162-170) or MQNIMNDMP (SEQ ID NO: 2, residues 55-63),
where said peptide of SLLGLKDQV (SEQ ID NO: 2, residues 961-969), GLTRTSVTV (SEQ ID NO: 2, residues 391-399), KLNVEERSV (SEQ ID NO: 2, residues 162-170) or MQNIMNDMP (SEQ ID NO: 2, residues 55-63):
(i) has up to one conservative amino acid substitution within the conservative substitution groups (a) S and T, (b) L, I and V, and (c) E and D; and
(ii) retains the ability to stimulate a T-cell immune response to EphA2 as determined by ELISPOT assay, and a pharmaceutically acceptable carrier.
7. The vaccine formulation of claim 6 , where the isolated peptide comprises the peptide SLLGLKDQV (SEQ ID NO: 2, residues 961-969).
8. The vaccine formulation of claim 6 , where the isolated peptide comprises the peptide GLTRTSVTV (SEQ ID NO: 2, residues 391-399).
9. The vaccine formulation of claim 6 , where the isolated peptide comprises the peptide KLNVEERSV (SEQ ID NO: 2, residues 162-170).
10. The vaccine formulation of claim 6 , where the isolated peptide comprises the peptide MQNVIMNDMP (SEQ ID NO: 2, residues 55-63).
11. The vaccine formulation of claim 6 , further comprising an adjuvant.
12. The vaccine formulation of claim 7 , further comprising an adjuvant.
13. The vaccine formulation of claim 8 , further comprising an adjuvant.
14. The vaccine formulation of claim 9 , further comprising an adjuvant.
15. The vaccine formulation of claim 10 , further comprising an adjuvant.
16. The vaccine formulation of claim 6 , wherein the isolated peptide comprises a second peptide where said second peptide is not an EphA2 peptide and is immunogenic.
17. The vaccine formulation of claim 7 , wherein the isolated peptide comprises a second peptide where said second peptide is not an EphA2 peptide and is immunogenic.
18. The vaccine formulation of claim 8 , wherein the isolated peptide comprises a second peptide where said second peptide is not an EphA2 peptide and is immunogenic.
19. The vaccine formulation of claim 9 , wherein the isolated peptide comprises a second peptide where said second peptide is not an EphA2 peptide and is immunogenic.
20. The vaccine formulation of claim 10 , wherein the isolated peptide comprises a second peptide where said second peptide is not an EphA2 peptide and is immunogenic.
21. A method of eliciting an immune response to EphA2 in a subject, comprising administering, to the subject, an effective amount of an isolated peptide that consists of 9-35 amino acid residues and wherein said isolated peptide comprises the peptide of SLLGLKDQV (SEQ ID NO: 2, residues 961-969), GLTRTSVTV (SEQ ID NO: 2, residues 391-399), KLNVEERSV (SEQ ID NO: 2, residues 162-170) or MQNIMNDMP (SEQ ID NO: 2, residues 55-63),
where said peptide of SLLGLKDQV (SEQ ID NO: 2, residues 961-969), GLTRTSVTV (SEQ ID NO: 2, residues 391-399), KLNVEERSV (SEQ ID NO: 2, residues 162-170) or MQNIMNDMP (SEQ ID NO: 2, residues 55-63):
(i) has up to one conservative amino acid substitution within the conservative substitution groups (a) S and T, (b) L, I and V, and (c) E and D; and
(ii) retains the ability to stimulate a T-cell immune response to EphA2 as determined by ELISPOT assay.
22. A method of eliciting an immune response to EphA2 in a subject, comprising administering, to the subject, an effective amount of a vaccine formulation comprising an isolated peptide that consists of 9-35 amino acid residues, wherein said isolated peptide comprises the peptide of SLLGLKDQV (SEQ ID NO: 2, residues 961-969), GLTRTSVTV (SEQ ID NO: 2, residues 391-399), KLNVEERSV (SEQ ID NO: 2, residues 162-170) or MQNIMNDMP (SEQ ID NO: 2, residues 55-63),
where said peptide of SLLGLKDQV (SEQ ID NO: 2, residues 961-969), GLTRTSVTV (SEQ ID NO: 2, residues 391-399), KLNVEERSV (SEQ ID NO: 2, residues 162-170) or MQNIMNDMP (SEQ ID NO: 2, residues 55-63):
(i) has up to one conservative amino acid substitution within the conservative substitution groups (a) S and T, (b) L, I and V, and (c) E and D; and
(ii) retains the ability to stimulate a T-cell immune response to EphA2 as determined by ELISPOT assay, and a pharmaceutically acceptable carrier.